Drilldown: Medicines - Pharmacopedia

Nav

Choose a table:

Medicines (732)

Medicines > generic: None

& classes

: Dissociative

or Neuroactive steroid

Use the filters below to narrow your results.

Spravato (1) · Zulresso (1) · Zurzuvae (1)

None (2) · Synthetic neuroactive steroid (an analog of allopregnanolone), bioavailable orally unlike brexanolone. Positive allosteric modulator at GABA-A receptors including extrasynaptic δ-containing subtypes. (1)

Postpartum depression (PPD) in adults (1) · Postpartum depression (PPD) in adults (FDA-approved 2023) (1) · Treatment-resistant depression (TRD) in adults, as adjunct to oral antidepressant (FDA-approved March 2019). Depressive symptoms in adults with MDD with acute suicidal ideation or behavior (FDA-approved Aug 2020). (1)

50 mg PO once daily with fatty food in the evening × 14 days (1) · Induction (TRD): 56 mg intranasal twice weekly × 4 weeks. Maintenance: 56-84 mg once weekly × 4 weeks, then 56-84 mg every 1-2 weeks. For acute suicidality: 84 mg twice weekly × 4 weeks. Administered under medical supervision in REMS-certified site. (1) · Single 60-hour continuous IV infusion: 30 mcg/kg/h × 4h → 60 mcg/kg/h × 20h → 90 mcg/kg/h × 28h → 60 mcg/kg/h × 4h → 30 mcg/kg/h × 4h (1)

100 mg/20 mL vial, single-use (1) · 20 mg, 25 mg, 30 mg capsules (1) · 28 mg/device (each dose uses 2 devices) (1)

50 mg/d × 14 d (1) · 84 mg per session (1) · Single 60-hour course (1)

Intranasal (under direct medical supervision) (1) · Intravenous (continuous infusion in a REMS-certified facility) (1) · Oral (1)

Antidepressant effect within hours of infusion start; sustained at 30 days (1) · Day 3 of dosing in trials; sustained through day 45 (1) · Within hours of first administration (1)

14-day course; effect persists after discontinuation in trials (1) · Acute effect ~24 hours; cumulative effect builds with repeated dosing (1) · Single infusion course (1)

~16-23 hours (1) · ~7-12 hours (1) · ~9 hours (terminal) (1)

100% (IV) (1) · Adequate (food-dependent, must take with fatty meal) (1) · ~48% intranasal (1)

Avoid; may cause fetal harm (1) · Limited data; avoid in pregnancy. Lactation: present in milk; consider risks (1) · Medicine is structurally identical to endogenous allopregnanolone; pregnancy considerations relate to breastfeeding during/after infusion. Limited data; brief interruption of breastfeeding considered (1)

Rx, Schedule III (US). REMS program required. (1) · Rx, Schedule IV (US) (1) · Rx; REMS program required (excessive sedation/loss of consciousness during infusion) (1)

Showing below up to 3 results in range #1 to #3.

B

Brexanolone

E

Esketamine

Z

Zuranolone

Retrieved from "https://pharmacopedia.wiki/p/Special:Drilldown/Medicines"